Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;43(3):102-107.
doi: 10.36185/2532-1900-447.

Transition and management of patients with Duchenne Muscular Dystrophy: a narrative review based on Italian experts' opinion and real-world experience

Carlotta Spagnoli  1 , Rachele Adorisio  2 , Luca Bello  3 , Adele D'Amico  4 , Maria Grazia D'Angelo  5 , Marika Pane  6 , Martina Penzo  3 , Pietro Riguzzi  3 , Valeria Sansone  7 , Andrea Vianello  8 , Carlo Fusco  1
Affiliations
Review

Transition and management of patients with Duchenne Muscular Dystrophy: a narrative review based on Italian experts' opinion and real-world experience

Carlotta Spagnoli et al. Acta Myol. 2024 Sep.

Abstract

Objectives: Duchenne Muscular Dystrophy (DMD) is a severe, progressive, X-linked disorder resulting in muscle wasting, progressive functional loss and cardiomyopathy. Therapeutic strategies feature glucocorticoid corticosteroids plus gene therapy/stop codon read-through, plus standards of care. Prolonged survival, delayed loss of ambulation (LoA), and innovative treatment prescriptions pose new clinical challenges, including identification of new outcome measures/targets and implementation of continuity of care.

Methods: We report on the results of an Italian experts' meeting held in Rome, Italy on 20th April 2022. We aimed to: discuss challenges linked to transitioning from the ambulatory to the non-ambulatory phase, and from pediatric to adult care; collect experience on the importance of ongoing care and treatment in advanced disease stages and on the need to measure clinically relevant outcomes during disease progression after LoA.

Results: Following LoA the main management focus shifts to cardiac, respiratory, orthopaedics, nutrition and upper limbs function. More data on clinical needs, available treatments, standards of care, frequency of follow-up, and transition should be collected in order to facilitate management optimisation. Shared protocols should be developed, especially to improve patients' management in the acute setting.

Conclusions: Transition from paediatric to adult services and from the ambulatory to the non-ambulatory phase require a multidisciplinary approach and the Identification of clinically meaningful outcome measures, which should be described in long-term longitudinal studies.

Keywords: Duchenne muscular dystrophy; ataluren; loss of ambulation; transition.

PubMed Disclaimer

Conflict of interest statement

Luca Bello reports honoraria (speaker, consultancy) for PTC Therapeutics, Sarepta Therapeutics, Epirium Bio, Edgewise Therapeutics; research funding from PTC Therapeutics, Santhera Pharmaceuticals.

Carlotta Spagnoli, Rachele Adorisio, Adele D’Amico, Maria Grazia D’Angelo, Marika Pane, Valeria Sansone, Andrea Vianello, and Carlo Fusco report no conflicts of interest to disclose.

References

    1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. https://doi.org/10.1038/s41572-021-00248-3. 10.1038/s41572-021-00248-3 - DOI - PMC - PubMed
    1. Birnkrant DJ, Bushby K, Bann CM, et al. . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251-267. https://doi.org/10.1016/S1474-4422(18)30024-3 10.1016/S1474-4422(18)30024-3 - DOI - PMC - PubMed
    1. Birnkrant DJ, Bushby K, Bann CM, et al. . Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347-361. https://doi.org/10.1016/S1474-4422(18)30025-5 10.1016/S1474-4422(18)30025-5 - DOI - PMC - PubMed
    1. Birnkrant DJ, Bushby K, Bann CM, et al. . Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17:445-455. https://doi.org/10.1016/S1474-4422(18)30026-7 10.1016/S1474-4422(18)30026-7 - DOI - PMC - PubMed
    1. Bushby K, Finkel R, Wong B, et al. . Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50, 477-487. https://doi.org/10.1002/mus.24332. 10.1002/mus.24332 - DOI - PMC - PubMed

LinkOut - more resources